Editor's Note

Making India's Pharma Space Future-Ready

The Pharma IPR (Intellectual Property Rights) consulting sector has been showcasing quite a positive growth as we traverse 2026. This momentum can be primarily attributed to the upcoming patent "off-patent supercycle," where nearly USD 250 billion worth of innovator drugs are expected to go off-patent, necessitating strategic legal consulting.

Furthermore, the market is growing due to the need for navigating complex global regulatory landscapes (FDA, EMA, WHO), handling Hatch-Waxman litigation, and managing patent portfolios for both innovative and generic companies....  >>More